U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Triple-Class Exposed

MedGen UID:
1791433
•Concept ID:
C5554992
•
Finding

Definition

A finding indicating that a plasma cell myeloma patient has received the following three classes of treatment: proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVTriple-Class Exposed

Professional guidelines

PubMed

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Nooka AK, Rodriguez C, Mateos MV, Manier S, Chastain K, Banerjee A, Kobos R, Qi K, Verona R, Doyle M, Martin TG, van de Donk NWCJ
Cancer 2024 Mar 15;130(6):886-900. Epub 2023 Nov 14 doi: 10.1002/cncr.35107. PMID: 37960969
Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma.
Hlavacek P, Schepart A, Silverstein AR, Petrilla AA, Johnson W, Schroeder A
Future Oncol 2023 Apr;19(11):775-787. Epub 2023 May 3 doi: 10.2217/fon-2022-1018. PMID: 37132520
Antibody drug conjugates for the treatment of multiple myeloma.
Leong S, Lam HPJ, Kirkham Z, Popat R
Am J Hematol 2023 Mar;98 Suppl 2:S22-S34. Epub 2022 Oct 24 doi: 10.1002/ajh.26750. PMID: 36199262

Recent clinical studies

Etiology

Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
Mateos MV, Chari A, Usmani SZ, Goldschmidt H, Weisel K, Qi K, Londhe A, Nair S, Lin X, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Moreau P
Clin Lymphoma Myeloma Leuk 2023 May;23(5):385-393. Epub 2023 Mar 3 doi: 10.1016/j.clml.2023.02.006. PMID: 36967244
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
Moreau P, van de Donk NWCJ, Delforge M, Einsele H, De Stefano V, Perrot A, Besemer B, Pawlyn C, Karlin L, Manier S, Leleu X, Weisel K, Ghilotti F, Diels J, Elsada A, Morano R, Strulev V, Pei L, Kobos R, Smit J, Slavcev M, Mateos MV
Adv Ther 2023 May;40(5):2412-2425. Epub 2023 Mar 24 doi: 10.1007/s12325-023-02480-7. PMID: 36961654Free PMC Article
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S
N Engl J Med 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10 doi: 10.1056/NEJMoa2213614. PMID: 36762851
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.
Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J, Dytfeld D, Angelucci E, Perrot A, Benjamin R, van de Donk NWCJ, Ocio EM, Scheid C, Gay F, Roeloffzen W, Rodriguez-Otero P, Broijl A, Potamianou A, Sakabedoyan C, Semerjian M, Keim S, Strulev V, Schecter JM, Vogel M, Wapenaar R, Nesheiwat T, San-Miguel J, Sonneveld P, Einsele H, Moreau P
Leukemia 2022 May;36(5):1371-1376. Epub 2022 Mar 24 doi: 10.1038/s41375-022-01531-2. PMID: 35332278Free PMC Article
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T, Usmani SZ, Schecter JM, Vogel M, Jackson CC, Deraedt W, Tian H, Yeh TM, Banerjee A, Pacaud L, Garrett A, Haltner A, Cameron C, Van Sanden S, Diels J, Valluri S, Samjoo IA
Curr Med Res Opin 2021 Oct;37(10):1779-1788. Epub 2021 Jul 23 doi: 10.1080/03007995.2021.1953456. PMID: 34256668

Diagnosis

Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P
Lancet Haematol 2024 Mar;11(3):e216-e227. doi: 10.1016/S2352-3026(24)00005-X. PMID: 38423700
Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database.
Leleu X, Gorsh B, Bessou A, Paka P, De Nascimento J, Colin X, Landi S, Wang PF
Eur J Haematol 2023 Jul;111(1):125-134. Epub 2023 May 18 doi: 10.1111/ejh.13976. PMID: 37199133
Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma.
Hlavacek P, Schepart A, Silverstein AR, Petrilla AA, Johnson W, Schroeder A
Future Oncol 2023 Apr;19(11):775-787. Epub 2023 May 3 doi: 10.2217/fon-2022-1018. PMID: 37132520
Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study.
Dhanasiri S, Hollier-Hann G, Stothard C, Dhanda DS, Davies FE, Rodriguez-Otero P
Clin Ther 2021 Nov;43(11):1983-1996.e3. Epub 2021 Nov 2 doi: 10.1016/j.clinthera.2021.09.013. PMID: 34736769
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
Madduri D, Hagiwara M, Parikh K, Pelletier C, Delea TE, Kee A, Chari A
Future Oncol 2021 Feb;17(5):503-515. Epub 2020 Dec 2 doi: 10.2217/fon-2020-1003. PMID: 33522834

Therapy

Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
Mateos MV, Chari A, Usmani SZ, Goldschmidt H, Weisel K, Qi K, Londhe A, Nair S, Lin X, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Moreau P
Clin Lymphoma Myeloma Leuk 2023 May;23(5):385-393. Epub 2023 Mar 3 doi: 10.1016/j.clml.2023.02.006. PMID: 36967244
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
Moreau P, van de Donk NWCJ, Delforge M, Einsele H, De Stefano V, Perrot A, Besemer B, Pawlyn C, Karlin L, Manier S, Leleu X, Weisel K, Ghilotti F, Diels J, Elsada A, Morano R, Strulev V, Pei L, Kobos R, Smit J, Slavcev M, Mateos MV
Adv Ther 2023 May;40(5):2412-2425. Epub 2023 Mar 24 doi: 10.1007/s12325-023-02480-7. PMID: 36961654Free PMC Article
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S
N Engl J Med 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10 doi: 10.1056/NEJMoa2213614. PMID: 36762851
Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ
N Engl J Med 2022 Aug 11;387(6):495-505. Epub 2022 Jun 5 doi: 10.1056/NEJMoa2203478. PMID: 35661166Free PMC Article
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.
Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J, Dytfeld D, Angelucci E, Perrot A, Benjamin R, van de Donk NWCJ, Ocio EM, Scheid C, Gay F, Roeloffzen W, Rodriguez-Otero P, Broijl A, Potamianou A, Sakabedoyan C, Semerjian M, Keim S, Strulev V, Schecter JM, Vogel M, Wapenaar R, Nesheiwat T, San-Miguel J, Sonneveld P, Einsele H, Moreau P
Leukemia 2022 May;36(5):1371-1376. Epub 2022 Mar 24 doi: 10.1038/s41375-022-01531-2. PMID: 35332278Free PMC Article

Prognosis

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Nooka AK, Rodriguez C, Mateos MV, Manier S, Chastain K, Banerjee A, Kobos R, Qi K, Verona R, Doyle M, Martin TG, van de Donk NWCJ
Cancer 2024 Mar 15;130(6):886-900. Epub 2023 Nov 14 doi: 10.1002/cncr.35107. PMID: 37960969
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
Mateos MV, Chari A, Usmani SZ, Goldschmidt H, Weisel K, Qi K, Londhe A, Nair S, Lin X, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Moreau P
Clin Lymphoma Myeloma Leuk 2023 May;23(5):385-393. Epub 2023 Mar 3 doi: 10.1016/j.clml.2023.02.006. PMID: 36967244
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
Moreau P, van de Donk NWCJ, Delforge M, Einsele H, De Stefano V, Perrot A, Besemer B, Pawlyn C, Karlin L, Manier S, Leleu X, Weisel K, Ghilotti F, Diels J, Elsada A, Morano R, Strulev V, Pei L, Kobos R, Smit J, Slavcev M, Mateos MV
Adv Ther 2023 May;40(5):2412-2425. Epub 2023 Mar 24 doi: 10.1007/s12325-023-02480-7. PMID: 36961654Free PMC Article
Cellular therapy for multiple myeloma: what's now and what's next.
Rodriguez-Otero P, San-Miguel JF
Hematology Am Soc Hematol Educ Program 2022 Dec 9;2022(1):180-189. doi: 10.1182/hematology.2022000396. PMID: 36485132Free PMC Article
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T, Usmani SZ, Schecter JM, Vogel M, Jackson CC, Deraedt W, Tian H, Yeh TM, Banerjee A, Pacaud L, Garrett A, Haltner A, Cameron C, Van Sanden S, Diels J, Valluri S, Samjoo IA
Curr Med Res Opin 2021 Oct;37(10):1779-1788. Epub 2021 Jul 23 doi: 10.1080/03007995.2021.1953456. PMID: 34256668

Clinical prediction guides

Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P
Lancet Haematol 2024 Mar;11(3):e216-e227. doi: 10.1016/S2352-3026(24)00005-X. PMID: 38423700
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
Dima D, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H, Shune L, Kaur G, Khouri J, Afrough A, Strouse C, Lochner J, Mahmoudjafari Z, Raza S, Valent J, Anderson LD Jr, Anwer F, Abdallah AO, Hashmi H
Transplant Cell Ther 2024 Mar;30(3):308.e1-308.e13. Epub 2023 Dec 26 doi: 10.1016/j.jtct.2023.12.016. PMID: 38151105
Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma.
Hlavacek P, Schepart A, Silverstein AR, Petrilla AA, Johnson W, Schroeder A
Future Oncol 2023 Apr;19(11):775-787. Epub 2023 May 3 doi: 10.2217/fon-2022-1018. PMID: 37132520
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
Krishnan A, Nooka AK, Chari A, Garfall AL, Martin TG, Nair S, Lin X, Qi K, Londhe A, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Usmani SZ
J Comp Eff Res 2023 Jun;12(6):e220186. Epub 2023 Apr 28 doi: 10.57264/cer-2022-0186. PMID: 37114426Free PMC Article
Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients.
Sanoyan DA, Seipel K, Bacher U, Kronig MN, Porret N, Wiedemann G, Daskalakis M, Pabst T
BMC Cancer 2023 Apr 15;23(1):345. doi: 10.1186/s12885-023-10824-3. PMID: 37061680Free PMC Article

Recent systematic reviews

Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations.
Shah N, Sussman M, Crivera C, Valluri S, Benner J, Jagannath S
Clin Drug Investig 2021 Mar;41(3):201-210. Epub 2021 Feb 18 doi: 10.1007/s40261-021-01012-x. PMID: 33598857

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...